Skip to content

Pecs Block vs Local Infiltration in Mastectomy

Comparison Between Pectoral Nerve Block II and Local Anesthesia Infiltration of Isobaric Bupivacaine 0.25% 50 MG on Neutrophil-Lymphocyte Ratio, Interleukin-6 Levels, Pain Intensity, and Post-surgical Opioid Requirements in Modified Radical Mastectomy Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06451705
Acronym
PBLIM
Enrollment
30
Registered
2024-06-11
Start date
2024-03-01
Completion date
2024-04-30
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

postoperative pain, modified radical mastectomy, peripheral nerve block, local infiltration anesthesia, pectoralis nerve block

Brief summary

Studied the comparison between PECS II block and LIA on pain intensity, opioid requirements, RNL, and postoperative IL-6 levels in MRM patients.

Interventions

Treatment group that received the PECS II block using isobaric bupivacaine 0.5% 50 mg

DRUGLIA

Treatment group that received the local infiltration anesthesia using isobaric bupivacaine 0.5% 50 mg

Sponsors

Hasanuddin University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

single-blind randomized trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age: 18-60 years old. 2. Body weight (BW): 50-70 kg. 3. Height (TB): 150-170 cm. 4. Body mass index (BMI): 18.5-29.9 kg/m2. 5. American Society of Anesthesiologists physical status (ASA PS) class I-II. 6. Patients undergoing elective MRM surgery under general anesthesia.

Exclusion criteria

1. Patients with contraindications to PECS II block. 2. Patients with contraindications to LIA. 3. Patients with coagulation disorders or receiving anticoagulant therapy. 4. Patients with a history of chronic pain. 5. Patients with a history of allergy to study materials. 6. Patients with a history of previous breast surgery. 7. Patient refuses to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Concentration of Plasma Interleukin-61 hour before surgery, 2 hour after surgery, 12 hour after surgeryin pg/dL
Neutrophil-lymphocyte ratio1 hour before surgery, 2 hour after surgery, 12 hour after surgeryNeutrophil divided by lymphocyte
Pain intensity (Using Numeric Rating Scale)hour 0, 2, 4, 6, 12, 24Scale from 0-10, lower score = better outcome
Rescue opioid requirementWithin 24 hours after surgeryUsing fentanyl at a dose of 0.5-1 μg/kg/IV titrated as needed, in mcg (given if the patient had NRS of \>4/10)

Secondary

MeasureTime frameDescription
Time until first rescue opioid requirementWithin 24 hours after surgeryin minutes
Nausea and vomitingWithin 24 hours after surgeryNausea and vomiting were assessed using a numerical scale (0 = no nausea, 1 = mild nausea, 2 = severe nausea or vomiting once, and 3 = vomiting more than once). If the score was \> 2, rescue antiemetics with ondansetron 0.1 mg/IV were given.
Demographic baseline databaseline (before the surgery)Medical record number, age, body weight (in kilogram), height (in centimeter), BMI (in kg/m2), ASA PS class, duration of surgery (in minutes)

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026